Roivant drug meets mid-stage goals; ROIV shares jump premarket
Roivant (ROIV) said its experimental drug met the main goals of a mid-stage study in patients with high blood pressure associated with a type of lung disease, sending shares up about 20% in premarket trading.
Roivant NASDAQ:ROIV said on Tuesday its experimental drug met the main goals of a mid-stage study in patients with high blood pressure associated with a type of lung disease, sending shares up about 20% in premarket trading.Roivant has been expanding its late-stage pipeline after winning U.S. appro…